222 related articles for article (PubMed ID: 27697580)
1. Nanoknife Electroporation Ablation Trial: A Prospective Development Study Investigating Focal Irreversible Electroporation for Localized Prostate Cancer.
Valerio M; Dickinson L; Ali A; Ramachadran N; Donaldson I; Mccartan N; Freeman A; Ahmed HU; Emberton M
J Urol; 2017 Mar; 197(3 Pt 1):647-654. PubMed ID: 27697580
[TBL] [Abstract][Full Text] [Related]
2. Image-guided Irreversible Electroporation of Localized Prostate Cancer: Functional and Oncologic Outcomes.
Collettini F; Enders J; Stephan C; Fischer T; Baur ADJ; Penzkofer T; Busch J; Hamm B; Gebauer B
Radiology; 2019 Jul; 292(1):250-257. PubMed ID: 31161973
[TBL] [Abstract][Full Text] [Related]
3. Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study.
Ahmed HU; Hindley RG; Dickinson L; Freeman A; Kirkham AP; Sahu M; Scott R; Allen C; Van der Meulen J; Emberton M
Lancet Oncol; 2012 Jun; 13(6):622-32. PubMed ID: 22512844
[TBL] [Abstract][Full Text] [Related]
4. Oncological and Quality-of-life Outcomes Following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-monitored Prospective Cohort.
Blazevski A; Scheltema MJ; Yuen B; Masand N; Nguyen TV; Delprado W; Shnier R; Haynes AM; Cusick T; Thompson J; Stricker P
Eur Urol Oncol; 2020 Jun; 3(3):283-290. PubMed ID: 31103721
[TBL] [Abstract][Full Text] [Related]
5. Prostate Radiofrequency Focal Ablation (ProRAFT) Trial: A Prospective Development Study Evaluating a Bipolar Radiofrequency Device to Treat Prostate Cancer.
Orczyk C; Barratt D; Brew-Graves C; Peng Hu Y; Freeman A; McCartan N; Potyka I; Ramachandran N; Rodell R; Williams NR; Emberton M; Ahmed HU
J Urol; 2021 Apr; 205(4):1090-1099. PubMed ID: 33315505
[TBL] [Abstract][Full Text] [Related]
6. A prospective development study investigating focal irreversible electroporation in men with localised prostate cancer: Nanoknife Electroporation Ablation Trial (NEAT).
Valerio M; Dickinson L; Ali A; Ramachandran N; Donaldson I; Freeman A; Ahmed HU; Emberton M
Contemp Clin Trials; 2014 Sep; 39(1):57-65. PubMed ID: 25072507
[TBL] [Abstract][Full Text] [Related]
7. Patient Reported Outcome Measures for Transperineal Template Prostate Mapping Biopsies in the PICTURE Study.
Miah S; Eldred-Evans D; Simmons LAM; Shah TT; Kanthabalan A; Arya M; Winkler M; McCartan N; Freeman A; Punwani S; Moore CM; Emberton M; Ahmed HU
J Urol; 2018 Dec; 200(6):1235-1240. PubMed ID: 29940251
[TBL] [Abstract][Full Text] [Related]
8. A Multicenter, Randomized, Single-blind, 2-Arm Intervention Study Evaluating the Adverse Events and Quality of Life After Irreversible Electroporation for the Ablation of Localized Low-intermediate Risk Prostate Cancer.
de la Rosette J; Dominguez-Escrig J; Zhang K; Teoh J; Barret E; Ramon-Borja JC; Muir G; Bohr J; de Reijke T; Ng CF; Leung CH; Sanchez-Salas R; Laguna P
J Urol; 2023 Feb; 209(2):347-353. PubMed ID: 36441776
[TBL] [Abstract][Full Text] [Related]
9. Focal Ablation Targeted to the Index Lesion in Multifocal Localised Prostate Cancer: a Prospective Development Study.
Ahmed HU; Dickinson L; Charman S; Weir S; McCartan N; Hindley RG; Freeman A; Kirkham AP; Sahu M; Scott R; Allen C; Van der Meulen J; Emberton M
Eur Urol; 2015 Dec; 68(6):927-36. PubMed ID: 25682339
[TBL] [Abstract][Full Text] [Related]
10. Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue in Patients with Localized Prostate Cancer: A Prospective Phase 1 Clinical Trial.
Chin JL; Billia M; Relle J; Roethke MC; Popeneciu IV; Kuru TH; Hatiboglu G; Mueller-Wolf MB; Motsch J; Romagnoli C; Kassam Z; Harle CC; Hafron J; Nandalur KR; Chronik BA; Burtnyk M; Schlemmer HP; Pahernik S
Eur Urol; 2016 Sep; 70(3):447-55. PubMed ID: 26777228
[TBL] [Abstract][Full Text] [Related]
11. Feasibility and safety of focal irreversible electroporation as salvage treatment for localized radio-recurrent prostate cancer.
Scheltema MJ; van den Bos W; Siriwardana AR; Kalsbeek AMF; Thompson JE; Ting F; Böhm M; Haynes AM; Shnier R; Delprado W; Stricker PD
BJU Int; 2017 Nov; 120 Suppl 3():51-58. PubMed ID: 28834167
[TBL] [Abstract][Full Text] [Related]
12. Focal Therapy of Prostate Cancer Index Lesion With Irreversible Electroporation. A Prospective Study With a Median Follow-up of 3 Years.
Miñana López B; Andrés Boville G; Barbas Bernardos G; Ancizu Marckert X; Torres Roca M; Labairu Huerta L; Villacampa Aubá F; Ramón de Fata Chillón F; Sanz Ortega J; Abengózar Muela M; Gallardo Madueño G; Benito Boíllos A; Alcázar Peral A; Díez-Caballero Alonso F
J Urol; 2023 Jan; 209(1):261-270. PubMed ID: 36073928
[TBL] [Abstract][Full Text] [Related]
13. Extensive Histological Sampling following Focal Therapy of Clinically Significant Prostate Cancer with High Intensity Focused Ultrasound.
Mortezavi A; Krauter J; Gu A; Sonderer J; Bruhin J; Reeve KA; Held L; Donati OF; Rupp NJ; Moch H; Sulser T; Eberli D
J Urol; 2019 Oct; 202(4):717-724. PubMed ID: 31042109
[TBL] [Abstract][Full Text] [Related]
14. Magnetic resonance imaging-transrectal ultrasound fusion focal cryotherapy of the prostate: A prospective development study.
Valerio M; Shah TT; Shah P; Mccartan N; Emberton M; Arya M; Ahmed HU
Urol Oncol; 2017 Apr; 35(4):150.e1-150.e7. PubMed ID: 27955940
[TBL] [Abstract][Full Text] [Related]
15. Pilot Study to Assess Safety and Clinical Outcomes of Irreversible Electroporation for Partial Gland Ablation in Men with Prostate Cancer.
Murray KS; Ehdaie B; Musser J; Mashni J; Srimathveeravalli G; Durack JC; Solomon SB; Coleman JA
J Urol; 2016 Sep; 196(3):883-90. PubMed ID: 27113966
[TBL] [Abstract][Full Text] [Related]
16. Phase II Evaluation of Magnetic Resonance Imaging Guided Focal Laser Ablation of Prostate Cancer.
Eggener SE; Yousuf A; Watson S; Wang S; Oto A
J Urol; 2016 Dec; 196(6):1670-1675. PubMed ID: 27449263
[TBL] [Abstract][Full Text] [Related]
17. The Effects of Focal Therapy for Prostate Cancer on Sexual Function: A Combined Analysis of Three Prospective Trials.
Yap T; Ahmed HU; Hindley RG; Guillaumier S; McCartan N; Dickinson L; Emberton M; Minhas S
Eur Urol; 2016 May; 69(5):844-51. PubMed ID: 26525837
[TBL] [Abstract][Full Text] [Related]
18. Median 5-year outcomes of primary focal irreversible electroporation for localised prostate cancer.
Scheltema MJ; Geboers B; Blazevski A; Doan P; Katelaris A; Agrawal S; Barreto D; Shnier R; Delprado W; Thompson JE; Stricker PD
BJU Int; 2023 Jun; 131 Suppl 4():6-13. PubMed ID: 36495481
[TBL] [Abstract][Full Text] [Related]
19. Extended Focal Ablation of Localized Prostate Cancer With High-Frequency Irreversible Electroporation: A Nonrandomized Controlled Trial.
Wang H; Xue W; Yan W; Yin L; Dong B; He B; Yu Y; Shi W; Zhou Z; Lin H; Zhou Y; Wang Y; Shi Z; Ren S; Gao X; Wang L; Xu C
JAMA Surg; 2022 Aug; 157(8):693-700. PubMed ID: 35793110
[TBL] [Abstract][Full Text] [Related]
20. Effect of Focal vs Extended Irreversible Electroporation for the Ablation of Localized Low- or Intermediate-Risk Prostate Cancer on Early Oncological Control: A Randomized Clinical Trial.
Zhang K; Teoh J; Laguna P; Dominguez-Escrig J; Barret E; Ramon-Borja JC; Muir G; Bohr J; de Reijke TM; Pelechano Gómez P; Ng CF; Sanchez-Salas R; de la Rosette J
JAMA Surg; 2023 Apr; 158(4):343-349. PubMed ID: 36723911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
